Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma

NCT04137900 is registered in ClinicalTrials.gov with TopAlliance Biosciences as lead sponsor.

NCT NCT04137900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04137900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
Lead sponsor
TopAlliance Biosciences
Phase
Phase 1
Overall status
Unknown status
Start date
October 30, 2019
Completion date
March 31, 2026
Enrollment
499 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable solid tumor, metastatic solid tumor